Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Esperion Therapeutics reports results from phase II study of ETC-1002

June 10, 2013

Lipaglyn obtains approval in India for diabetic dyslipidemia

June 7, 2013

Andromeda reports on extension study of the phase III DIA-AID1 trial

June 7, 2013

BioMarin commences phase III program for PKU treatment candidate

June 6, 2013

Prolor Biotech begins pivotal phase III trial of hGH-CTP

June 6, 2013

PhaseBio begins first-in-human phase I study of long-acting basal insulin for diabetes

June 6, 2013

FDA grants priority review to Bristol-Myers Squibb and AstraZeneca's metreleptin

June 5, 2013

Novel GPR119 receptor agonists patented by Array BioPharma

June 5, 2013

Merck & Co. patents new series of DGAT1 inhibitors

June 5, 2013

Novel therapy discovered for X-linked adrenoleukodystrophy

June 5, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...